https://www.businesswire.com/news/home/20241112854138/en/Scholar-Rock-Reports-Third-Quarter-2024-Financial-Results-and-Highlights-Business-Progress
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometab...
scholar rockthird quarterfinancial resultsreportshighlights
https://www.businesswire.com/news/home/20260112295221/en/Scholar-Rock-Highlights-2026-Strategic-Priorities
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atr...
scholar rockstrategic prioritieshighlights